Back to dashboard
CommercialPrior AuthMedium impact

Pharmacy Policies Updates

Blue Cross Blue Shield of North Dakota·ND · Oncology, Hematology, Endocrinology·Pharmacy
Effective date
Jan 13, 2026
We identified it
Jun 19, 2026
Days to comply

Summary

Blue Cross Blue Shield of North Dakota updated prior authorization policies for multiple specialty pharmaceutical drugs effective January 13, 2026. Changes include authorization duration modifications, dosing limit updates, expanded indications for several cancer treatments, and addition of new biosimilar products.

Action Required

Action needed
By January 13, 2026: Billing teams must update prior authorization systems to reflect new authorization durations for specialty cancer drugs including Abecma, Adcetris, Breyanzi, and Carvykti. Update billing codes - discontinue using C9301 and J9999 (discontinued 07/01/2025), use Q2058 for Aucatzyl instead. Remove HCPCS J3590 for specific denosumab products discontinued 10/01/2025. Add new biosimilar products for aflibercept, denosumab, and IVIG to formulary systems. Update ICD-10 coding to include new pediatric lymphoma codes and remove outdated codes.

Affected Billing Codes

C9301
J9999
Q2058
J3590
C91.01
C65.1
C65.2
C65.9
C83.30
C83.31
C83.32
C83.33
C83.34
C83.35
C83.36
C83.37
C83.38
C83.39
C83.70
C83.71
C83.72
C83.73
C83.74
C83.75
C83.76
C83.77
C83.78
C83.79
C85.20
C85.21
C85.22
C85.23
C85.24
C85.25
C85.26
C85.27
C85.28
C85.29
D47.Z1
E78.01
E78.010